Daniel de Castro
Impact in
- Oncology top 0.2%
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 8
- Peptidase Inhibition and Analysis 3
- Colorectal Cancer Treatments and Studies 2
- Cancer Treatment and Pharmacology 2
- Co-authors
- Gary M. ClarkJosé Rodrigues PereiraMichael SmylieP. SantabárbaraSumitra ThongprasertLesley SeymourMircea DediuD. Johnston
In The Last Decade
Daniel de Castro
24 papers receiving 7.6k citations
Hit Papers
Peers
Comparison fields: 5 of 120
- Oncology 6.0k
- Pulmonary and Respiratory Medicine 4.5k
- Cancer Research 1.7k
- Hepatology 222
- Molecular Biology 1.7k
Countries citing papers authored by Daniel de Castro
This map shows the geographic impact of Daniel de Castro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel de Castro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel de Castro more than expected).
Fields of papers citing papers by Daniel de Castro
This network shows the impact of papers produced by Daniel de Castro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel de Castro. The network helps show where Daniel de Castro may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel de Castro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 3 | |
| 4 | 2023 | 2 | |
| 5 | 2023 | 15 | |
| 6 | 2023 | 8 | |
| 7 | 2022 | 4 | |
| 8 | 2022 | 0 | |
| 9 | 2022 | 3 | |
| 10 | 2022 | 14 | |
| 11 | 2021 | 22 | |
| 12 | 2020 | 9 | |
| 13 | 2020 | 12 | |
| 14 | 2013 | 2 | |
| 15 | 2011 | 7 | |
| 16 | 2009 | 1 | |
| 17 | Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group Hit paper breakdown → | 2007 | 2909 |
| 18 | Erlotinib in Previously Treated Non–Small-Cell Lung Cancer Hit paper breakdown → | 2005 | 4281 |
| 19 | 2003 | 290 | |
| 20 | [Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer]. | 1999 | 1 |
About Daniel de Castro
Daniel de Castro is a scholar working on Nephrology, Oncology, Internal Medicine, Cardiology and Cardiovascular Medicine and Hepatology, having authored 26 papers that have together received 7.8k indexed citations. Recurring topics across this work include Amyloidosis: Diagnosis, Treatment, Outcomes (4 papers), Peptidase Inhibition and Analysis (3 papers), Neuroendocrine Tumor Research Advances (2 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Liver Disease Diagnosis and Treatment (2 papers), Atrial Fibrillation Management and Outcomes (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Cancer Treatment and Pharmacology (2 papers). The work is most often cited by research in Oncology (6.0k citations), Pulmonary and Respiratory Medicine (4.5k citations), Cancer Research (1.7k citations), Hepatology (222 citations) and Molecular Biology (1.7k citations). Daniel de Castro has collaborated with scholars based in Spain, Brazil and Canada. Frequent co-authors include Gary M. Clark, José Rodrigues Pereira, Michael Smylie, P. Santabárbara, Sumitra Thongprasert, Lesley Seymour, Mircea Dediu, D. Johnston, Andrea Bezjak and Tudor–Eliade Ciuleanu. Their work appears in journals such as Journal of Clinical Oncology, European Heart Journal, Journal of Cardiovascular Development and Disease, JACC Heart Failure and European Heart Journal Acute Cardiovascular Care.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.